Literature DB >> 3117754

Pharmacodynamic aspects of in vitro and in vivo chemosensitivity tests.

Y Isobe1, T Kubota, F Asanuma, H Kurihara, T Inada, T Fukutomi, K Ishibiki, O Abe.   

Abstract

To determine the optimal conditions for clonogenic assay, the antitumor activities of 5-fluorouracil (5-FU) in vitro and in vivo were compared from a pharmacodynamic viewpoint in a human carcinoma xenograft-nude mouse system. In the clonogenic assay, tumor cells were exposed to 5-FU continuously for 2 weeks, and the results of the assay were evaluated in terms of colony survival rates (T/C). Tumor-bearing BALB/c male nude mice were treated with 5-FU, and the results were evaluated in terms of the lowest values of relative mean tumor weights (T/C). To compute the area under the curve (AUC) after administration of 5-FU in vitro and in vivo, agar and serum levels of 5-FU were measured by bioassay. Antitumor activities in terms of T/Cs against a gastric carcinoma strain (H-111) depended highly on the AUCs in vitro and in vivo. The T/C in vitro (z) was correlated with the AUC in vitro (w), z = 58.4 x 0.99331w, and the T/C in vivo (y) was also correlated with the AUC in vivo (x), y = 52.1 x 0.88552x. On the assumption that the T/Cs of these two regression equations were equivalent (y = z), a correlation between w and x was derived. To predict the T/C at the maximum tolerated dose of 5-FU in mice, the optimal drug concentration in vitro was calculated to be 2.7 micrograms/ml, which also proved to be suitable for seven other carcinoma strains. Our experimental system was thought to be adequate for selecting the optimal drug concentration in the clonogenic assay.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117754

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  3 in total

1.  A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer.

Authors:  T Inada; Y Ogata; T Kubota; I Ozawa; S Hishinuma; H Shimizu; K Kotake; T Ikeda; Y Koyama
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

2.  Interferon alpha-2a shows antitumor activity in combination with 5-fluorouracil against human colon carcinoma xenografts: a study in reference to thymidylate synthetase activity inhibition.

Authors:  T Kubota; T Inada; Y Ogata
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

3.  Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition.

Authors:  T Kubota; S Fujita; S Kodaira; T Yamamoto; K Josui; Y Arisawa; A Suto; K Ishibiki; O Abe; K Mabuchi
Journal:  Jpn J Cancer Res       Date:  1991-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.